Pulmonx publishes investor presentation on Zephyr endobronchial valves for severe emphysema treatment
LUNG•Investor presentation highlights market opportunity and clinical data
- Pulmonx highlighted a USD 12 billion market opportunity for Zephyr endobronchial valves in severe emphysema.
- Reported 2Q26 revenue of USD 22.8 million, including USD 14.2 million in the US, with gross margin of 78%.
- Cash, cash equivalents, and marketable securities totaled USD 55.8 million as of 6/30/2026.
- Noted more than 50,000 patients treated globally, supported by four randomized trials and more than 100 scientific publications.
- Outlined AeriSeal as an investigational program aimed at converting some ineligible patients, with potential to expand addressable market by at least 20%.
